BOQI International Medical Inc. (NASDAQ:BIMI) stock opened at $5.03 in recent trading session and has moved within a range spread between a low of $3.9107 and a high of $5.03. When we look at the daily trading volume, traded BOQI International Medical Inc. shares reached 1.51 million, slightly higher than its 90-day average trading volume of 605070.0. The company has a market cap of $21.51 million. BIMI stock lost -20.58% on the day to settle at $4.09 with a 4.31% short float and a short ratio of 0.21.
Short term prospects for the stock appear exciting, with the distance to its 20-day simple moving average at +25.46% and the price target is given a consensus estimate of $3.07, about +0.83 up on the current stock price at $4.09. The weekly performance stands at 50.92% higher and 21.36% over the past one month. However, its overall year-to-date performance is up by 28.21% and -40.29% over the last 12 months.
If we break down the company’s shareholders to find out who the top BIMI holders are, we note that insiders hold only 77.94% of the shares. The major holders are institutions that hold 0.04% of the company’s shares, specifically spread out among 3 institutional holders. The Deutsche Bank Aktiengesellschaft currently holds 2944.0 shares (about 0.03% of shares outstanding) valued at over $3208.0 as reported last on Sep 29, 2019.
In terms of the stock price, analysts have given the stock a 12-month consensus price target of $4.09, with the low at $12.50 and the high at $12.50. The median price of $12.50 suggests that analysts predict the stock will gain by 67.28% over the year from the last trading price. If the stock climbs to hit the high price target, then the company’s share price would have surged by an impressive 67.28% over the next 12 months. Even hitting the consensus low price we would still see the stock rise 67.28% from its current price level.
OpGen Inc. (NASDAQ: OPGN) is undervalued, analysts say as the stock’s 5.00 rating makes it a Strong Buy. Meanwhile, the stock that has jumped to $1.80 by losing -0.47 in Tuesday’s market deals, received rating change over the recent past. Alliance Global Partners Initiated the Buy rating and set the stock’s price target to $2.30. H.C. Wainwright Reiterated the stock to Buy and has the OPGN stock price target for the year at $9. On June 29, 2016, Rodman & Renshaw issued an Initiated for OpGen Inc. (NASDAQ:OPGN) to Buy. Analysts, on average, believe could hit $2.50 per share within one year. The target price suggests that the company shares have a 0.0 downside potential compared to its last price at the close of trade at $2.27 (down -0.08% on day’s opening price on 02/04/20).
So, what do analysts say about a stock that has gained 59.29% year-to-date? Data shows that 1 analysts observing OpGen Inc.’s stock have recommended OPGN as a Buy. 1 of 1 say it is a buy, while 0 rate the stock as a overweight. The remaining 0 recommend investors Hold. The median price target for the stock is $2.50, with the range between a low of $2.50 and a high of $2.50. Shares outstanding sit at 5.41M while the public float is currently at 5.41M shares.
The average analyst ratings momentum for the stock is 5.00 and has remained 5.00 and 5.00 a month ago and 2 months ago, respectively. We focus on changes in the sentiment portrayed by analysts over a given timeframe to get a pointer regarding the stock’s future price movements. If we look at the stock’s most recent price movements, the SMA20 is at a distance of 14.65% while enlarging that period further brings the SMA50 and SMA200 to 31.88% and -66.90% respectively.
In terms of volatility relative to the latest price change, OPGN has a relative strength index (RSI) of 55.91 while the ATR figure stands at 0.29. Over the last week, the stock’s price swung only 20.00% although that rises to 57.89% over the month. Investors are encouraged by the negative sales in the quarter over quarter returns that currently stand at 0.00%. Sentiment is however tempered due to the 32.35% in quarter-over-quarter earnings a share. OpGen Inc. (OPGN) has a return on equity ratio of -690.10% according to the company’s trailing 12 month data, while the total return on investment stands at -253.50%.